Confronting the Delta Variant of SARS-CoV-2, Summer 2021

JAMA. 2021 Sep 21;326(11):1001-1002. doi: 10.1001/jama.2021.14811.

Authors

Carlos Del Rio^{1

2}, Preeti N Malani^{3

4}, Saad B Omer⁵

Affiliations

¹ Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia.
² Hubert Department of Global Health, Rollins School of Public Health of Emory University, Atlanta, Georgia.
³ Department of Internal Medicine, Division of Infectious Diseases, University of Michigan, Ann Arbor.
⁴ Associate Editor, JAMA.
⁵ Yale Institute for Global Health, New Haven, Connecticut.

PMID: 34406361
DOI: 10.1001/jama.2021.14811

No abstract available

MeSH terms

Antibodies, Viral
COVID-19 / prevention & control*
COVID-19 Vaccines / immunology*
Humans
Immunization Programs*
Immunocompromised Host
Immunogenicity, Vaccine*
SARS-CoV-2*
Seasons
United States
Vaccination / statistics & numerical data

Substances

Antibodies, Viral
COVID-19 Vaccines